Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRPR | P30550 | 5/20 | 0.70 |
| ▸ | CXCR4 | P61073 | 8/20 | 0.68 |
| ▸ | MC4R | P32245 | 1/20 | 0.66 |
| ▸ | MC5R | P33032 | 1/20 | 0.66 |
| ▸ | MC3R | P41968 | 1/20 | 0.66 |
| ▸ | MC1R | Q01726 | 1/20 | 0.66 |
| ▸ | NMBR | P28336 | 1/20 | 0.65 |
| ▸ | NPY1R | P25929 | 1/20 | 0.64 |
| ▸ | NPY2R | P49146 | 1/20 | 0.64 |
| ▸ | NPY4R | P50391 | 1/20 | 0.64 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.64 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.63 |
| ▸ | CALCA | P06881 | 1/20 | 0.62 |
| ▸ | TFPI | P10646 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29367990 | 0.92 | CALCA (0.69) | GRPRCXCR4MC4RMC5RMC3R | |
| SCHEMBL20764721 | 0.90 | GRPR (0.70) | GRPRCXCR4NMBRNPY1RNPY2R | |
| SCHEMBL29351953 | 0.89 | NPY2R (0.74) | CXCR4MC4RMC5RMC3RMC1R | |
| SCHEMBL29355231 | 0.89 | NPY1R (0.76) | CXCR4MC4RMC5RMC3RMC1R | |
| Water SCHEMBL29941416 | 0.89 | NPY1R (0.75) | CXCR4MC4RMC5RMC3RMC1R | |
| SCHEMBL29464570 | 0.88 | NPY2R (0.71) | CXCR4MC4RMC5RMC3RMC1R | |
| Acetic Acid SCHEMBL29399515 | 0.87 | NPY1R (0.75) | CXCR4MC4RMC5RMC3RMC1R | |
| SCHEMBL270044 | 0.86 | NPY1R (0.68) | CXCR4MC4RMC5RMC3RMC1R | |
| SCHEMBL31083828 | 0.86 | GLP1R (0.70) | GRPRNMBRNPY1RNPY2RNPY4R | |
| SCHEMBL29366899 | 0.86 | GLP1R (0.70) | GRPRNMBRNPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339567-A1 | COMPOUNDS WITH IMPROVED PHARMACOKINETICS FOR IMAGING AND THERAPY OF CANCER | UNIV MUENCHEN TECH (DE) | 2025-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339567-A1 | COMPOUNDS WITH IMPROVED PHARMACOKINETICS FOR IMAGING AND THERAPY OF CANCER | RXFP2, XPNPEP2, ANTXR2 | GRPR 11/4885CXCR4 497/4885MC4R 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.